Pikesville, MD, United States of America

Michel Bernier

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Sri International, The Cooper Health System. Active years: 2016-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michel Bernier. Retrieved from https://idiyas.com/inventor/michel-bernier-b39cuvru

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 34(Granted Patents)

Company Filing History:

11 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

The Cooper Health System

patents

where one patent can have more than one assignee

Years Active: 2016-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11389415 - Methods of regulating cannabinoid receptor activity-related disorders and diseases (2022-07-19),

2. 10925840 - Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas (2021-02-23),

3. 10772849 - Methods of regulating cannabinoid receptor activity-related disorders and diseases (2020-09-15),

4. 10617654 - Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas (2020-04-14),

5. 10485771 - Methods of regulating cannabinoid receptor activity-related disorders and diseases (2019-11-26),

6. 10130594 - Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas (2018-11-20),

7. 10130593 - Methods of regulating cannabinoid receptor activity-related disorders and diseases (2018-11-20),

8. 9867830 - Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain (2018-01-16),

9. 9650352 - Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain (2017-05-16),

10. 9492405 - Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas (2016-11-15),

Title: Michel Bernier: Innovator in Cannabinoid Research

Introduction

Michel Bernier is a notable inventor based in Pikesville, MD (US). He has made significant contributions to the field of cannabinoid receptor activity-related disorders and diseases. With a total of 10 patents to his name, Bernier's work focuses on innovative methods for treating various types of cancer.

Latest Patents

Among his latest patents, Bernier has developed methods for regulating cannabinoid receptor activity-related disorders and diseases. This includes the use of fenoterol analogues to treat conditions such as glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and lung cancer. His methods involve administering effective amounts of fenoterol analogues to subjects at risk of developing these disorders. Another significant patent involves the use of fenoterol and its analogues in treating tumors that express the β2-adrenergic receptor, specifically targeting primary brain tumors like glioblastomas and astrocytomas.

Career Highlights

Bernier has had a distinguished career, working with prominent organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and SRI International. His research has contributed to advancements in the understanding and treatment of cannabinoid-related disorders.

Collaborations

Throughout his career, Bernier has collaborated with esteemed colleagues, including Irving William Wainer and Rajib Kumar Paul. These partnerships have furthered his research and innovation in the field.

Conclusion

Michel Bernier's work in cannabinoid research exemplifies the impact of innovative thinking in medicine. His patents and collaborations highlight his commitment to advancing treatment options for serious health conditions.

Profile summary based on public USPTO records.